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OBJECTIVES We assessed whether the intravenous administration of nicorandil, an adenosine triphosphate
(ATP)-sensitive K1 channel opener, exerts beneficial effect on microvascular function and
functional and clinical outcomes in patients with acute myocardial infarction (AMI).
BACKGROUND Experimental studies documented that ATP-sensitive K1 channel opener exerts cardiopro-
tection after prolonged ischemia.
METHODS We randomly divided 81 patients with a first anterior AMI into two groups, nicorandil (n 5
40) and control groups (n 5 41). All patients received successful coronary angioplasty within
12 h after the symptom onset and underwent myocardial contrast echcardiography (MCE)
with the intracoronary injection of sonicated microbubbles. In the nicorandil group, we
injected 4 mg of nicorandil followed by the infusion at 6 mg/h for 24 h and by oral nicorandil
(15 mg/day).
RESULTS The improvement in regional left ventricular function, wall motion score and regional wall
motion was significantly better in the nicorandil group then in the control group. Intractable
congestive heart failure, malignant ventricular arrhythmia and pericardial effusion were more
frequently found in the control group than in the nicorandil group (15% vs. 37%, 5% vs. 20%
and 8% vs. 37%, p , 0.05, respectively). The frequency of sizable MCE no reflow
phenomenon was significantly lower in the nicorandil group than in the control group (15%
vs. 33%, p , 0.05).
CONCLUSIONS Intravenous nicorandil in conjunction with coronary angioplasty is associated with better
functional and clinical outcomes compared to angioplasty alone in patients with an anterior
AMI. Myocardial contrast echocardiography findings imply that an improvement in
microvascular function with nicorandil may be attributable to this better outcome. (J Am
Coll Cardiol 1999;33:654–60) © 1999 by the American College of Cardiology
Coronary reperfusion by the use of thrombolysis and/or
angioplasty has been established as an essential therapy of
acute myocardial infarction (AMI) (1–3). Recently, we and
other investigators demonstrated that pharmacologic treat-
ment, such as intracoronary verapamil or nicorandil and
adenosine, in conjunction with coronary reperfusion, can
enhance functional improvement of left ventricle in patients
with AMI (4–6). Among them, several experimental stud-
ies stressed that nicorandil, which is a hybrid of adenosine
triphosphate (ATP)-sensitive K1 channel opener and ni-
trates, can enhance the recovery of postischemic contractile
dysfunction and reduces infarct size (7–10). This cardiopro-
tective effect of nicorandil was documented in a clinically
relevant model, where nicorandil was given after a sustained
period of ischemia and continued throughout reperfusion
(10). The mechanism involved in the salutary actions of
nicorandil are not known for certain. Contribution of
reducing preload and afterload, anti–free radical and
neutrophil-modulating properties, the opening of KATP
channels and the vasodilatation of the small coronary
arteries have been postulated. Kitakaze et al. documented
that nicorandil mimics the effect of ischemic precondition-
ing in canine hearts (11). However, there is no clinical study
that nicorandil, if administrated intravenously, can limit
infarct size and improve functional and clinical outcomes
compared to coronary reperfusion alone.
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The goal of this study is to assess the effect of intravenous
nicorandil on the functional improvement, left ventricular
morphology, in-hospital complications and survival in pa-
tients with reperfused anterior wall AMI. We chose intra-
venous rather than intracoronary injection, because this
approach is easy and can be widely accepted in clinical
settings. To assess its mechanism of cardioprotection, we
also studied its effect on coronary microvasculature with
myocardial contrast echocardiography (MCE).
METHODS
Study population. From February 1994 through Novem-
ber 1996, 90 patients who were admitted to the Coronary
Care Unit of the Sakurabashi Watanabe Hospital for their
first myocardial infarction of the anterior wall and presented
Thrombolysis in Myocardial Infarction (TIMI) grade 0 or 1
flow (12) at initial coronary angiography were considered
study population. The diagnosis of AMI was made on the
basis of chest pain of $30 min duration, ST segment
elevation of $2 mm in two contiguous electrocardiographic
(ECG) leads and more than threefold increase in serum
creatine kinase activities. Nine patients were excluded from
analysis because of: inadequate image quality (four patients)
and coronary stenosis .90% in another coronary artery (five
patients). Therefore, this report is based on the remaining
81 patients. All patients underwent percutaneous translu-
minal coronary angioplasty and achieved successful coronary
reflow (TIMI grade 2 or 3) within 12 h after the symptom
onset. An investigator obtained written informed consent
from each patient. The study protocol was approved by the
hospital’s Ethics Committee.
Protocol. Just after the diagnosis of AMI, we randomly
divided patients into two groups, nicorandil and control
groups. After the bolus injection of nicorandil (4 mg)
(Sigmat, Chugai), it was continuously injected at 6 mg/h for
24 h followed by oral nicorandil 15 mg/day until the
discharge (a mean of 28 days) in the nicorandil group. Other
protocols were the same between the two groups. All
patients underwent cardiac catheterization with the use of
the femoral approach after the injection of 100 U/kg
heparin. After the injection of 0.3 mg of nitroglycerine into
the left coronary artery, we performed the coronary angiog-
raphy and left ventriculography. Then, we injected 2 ml of
sonicated ioxaglate (Hexabrix-360, Tanabe) containing mi-
crobubbles (mean size, 12 mm) into the left coronary artery
for MCE as previously described (13,14). We used a
mechanical sector scanner (model SAL-38B, Toshiba; car-
rier frequency, 3.5 MHz or SONOS 100, Hewlett-Packard;
carrier frequency, 2.5 MHz). We initiated imaging of the
apical long-axis view about 10 s before the contrast injection
and continued it for an average of 30 s with constant gain
setting. Myocardial contrast echocardiography images were
recorded on 1.25-cm videotape with a S-VHS recorder
(model AG-7350, Panasonic). We repeated MCE with the
contrast injection into the right coronary artery. We also
performed MCE a mean of 16 min (10 to 24 min) after
angioplasty.
After angioplasty, heparin was continued for 48 h and
was adjusted to maintain the activated clotting time to
.180 s. All patients were maintained on a regimen of
aspirin or ticlopidine and coumadine. If required, oral
nitrates, calcium antagonists, beta-adrenergic blocking
agents diuretics and/or angiotensin-converting enzyme in-
hibitors were added and continued until the late stage
examination. We continuously monitored a lead V5-
equivalent ECG until a mean of 7 days after the infarction
(range, 3 to 10 days) for detecting arrhythmia. We per-
formed the two-dimensional echocardiography on admis-
sion and at days 2, 3, 7 and 21 of the AMI with a
commercially available electrical sector scanner (SONOS
1500 or 2500, Hewlett-Packard, carrier frequency of 2.5 or
3.75 MHz) and recorded the images on 1.25-cm videotape
with the same S-VHS recorder. The presence or absence of
pericardial effusion was also evaluated. We repeated coro-
nary angiography and left ventriculography at a mean of 25
days after the AMI (range, 24 to 29 days) by use of the right
brachial approach.
Analysis of echocardiographic data. We analyzed echo-
cardiograms with a commercially available off-line computer
system (Color Cardiology Workstation, TomTec Imaging).
The details of analysis were described elsewhere (13–15). In
brief, an operator who did not know patients’ data selected
echocardiographic images with the best delineation between
contrast-enhanced and nonenhanced myocardium to deter-
mine risk area which was determined to be an area showing
contrast defect in the prereflow MCE images. Only when
the endocardial length of contrast perfusion defect after
angioplasty exceeded a quarter of that of the risk area was
myocardial reperfusion in the corresponding segment con-
sidered incomplete (MCE no reflow). Areas showing con-
trast defects were always successfully defined, and measure-
ments of the size of the residual contrast defects were highly
reproducible (13). Left ventricular wall motion was evalu-
ated at baseline and at follow-up (day 21) according to the
previously reported method (13). We scored 17 segments of
the left ventricle using the following system: 3, dys/akinetic;
2, severely hypokinetic; 1, hypokinetic; 0, normal. We
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defined a sum of segmental scores as wall motion score. Two
independent observers who did not know clinical data
determined the segmental score, and a third observer
established consensus in cases of disagreement.
Analysis of catheterization data. An angiographer blinded
to patient’ data analyzed the cinefilms in a random se-
quence. The right anterior oblique view of left ventriculo-
grams at acute and convalescent stages was analyzed. End-
diastolic volume and ejection fraction were measured with
the area-length method. The regional wall motion (standard
deviation/chord) of the territory of the left anterior descend-
ing coronary artery was analyzed with the centerline method
(16). The percent diameter stenosis after angioplasty and at
follow-up study was measured. Collateral channels were
graded following Rentrop classification (17).
In-hospital data collection. We followed up the patients
for the occurrence of complications until the time of
hospital discharge. We carefully collected data on clinically
relevant in-hospital events (death from any cause and
reinfarction) in the study forms. The type and frequency of
ventricular arrhythmias were evaluated from monitor ECG
in the catheter laboratory and in the Coronary Care Unit.
Malignant ventricular arrhythmia was defined as ventricular
tachycardia (a minimum of three consecutive beats of
ventricular origin at a rate of .100 beat/min) and ventric-
ular fibrillation found within 24 h after angioplasty. Con-
gestive heart failure (CHF) was diagnosed based on the
same clinical criteria as previously reported (18). Early
postinfarction angina was defined as angina pectoris ob-
served within 7 days after the onset of the AMI. Late
postinfarction angina was defined by angina pectoris found
beyond 7 days after the AMI and was evaluated mainly by
symptom-limited bicycle ergometer exercise test performed
at a mean of 25 days after the AMI (range, 24 to 27 days).
Pericardial effusion and cardiac tamponade were diagnosed
based on clinical and echocardiographic findings.
Statistical analysis. All data are expressed as mean 6 SD.
Univariate analyses of differences between control and
nicorandil groups were performed with one-way analysis of
variance (ANOVA) (Scheffe´ F test) for continuous outcome
variables and by chi-square tests or Fisher exact test for
discrete outcome variables. Statistical analysis of temporal
changes in certain variables was computed by ANOVA and
Scheffe´ F test for repeated measures. Differences were
considered significant at p , 0.05.
RESULTS
Forty patients received the intravenous and oral nicorandil,
and were designated as the nicorandil group. The other 41
patients were served as the control group. There were no
differences in age, gender, culprit lesion, time from the
symptom onset to reperfusion, heart rate, blood pressure,
frequency of non–Q wave AMI, collateral grade or risk
factors between the two groups (Table 1). There were also
no differences in the in-hospital medications other than
nicorandil between the two groups.
Complications and in-hospital prognosis. Table 2 com-
pares in-hospital ischemic events between the two groups.
The extension, early and late postinfarction angina, resten-
osis and reocclusion were rare, and their frequencies were
comparable between the two groups. Table 3 summarizes
in-hospital complications and survival of the two subsets.
Frequency of malignant ventricular arrhythmias within 24 h
after angioplasty was significantly higher in the control
group than the nicorandil group. Pericardial effusion was
observed more frequently in the control group than in the
nicorandil group. Cardiac tamponade was not found in the
nicorandil group, but it was observed in 10% of the control
Table 1. Clinical Characteristics of Study Patients
Characteristic
Nicorandil
(n 5 40)
Control
(n 5 41)
p
Value
Age (yr) 60 6 10 60 6 10 0.65
Male gender 32 (80) 32 (78) 0.83
Onset reperfusion (h) 4.8 6 2.2 5.3 6 2.2 0.28
Non-Q MI 3 (7) 3 (7) —
HR (beats/min)* 82 6 15 80 6 10 0.75
SBP (mm Hg)* 145 6 27 140 6 39 0.68
DBP (mm Hg)* 80 6 12 85 6 20 0.32
Preseptal 20 (50) 24 (59) 0.45
Collateral (grade $2)† 10 (25) 9 (22) 0.75
Risk factors
Diabetes mellitus 10 (25) 12 (29) 0.67
Hypertension 21 (53) 21 (51) 0.91
Hyperlipidemia 11 (27) 14 (34) 0.52
Smoking 24 (60) 21 (51) 0.43
In-hospital medications
Oral nitrates 33 (82) 31 (75) 0.49
Ca antagonists 17 (43) 17 (42) 0.97
Diuretics 4 (10) 7 (18) 0.29
Antiarrhythmic agents 3 (8) 7 (16) 0.26
ACE-inhibitors 29 (73) 28 (69) 0.70
Beta-blockers 6 (15) 7 (16) 0.92
*Values measured on admission. †Rentrop classification. Data are presented as
number of patients (percent) or mean value 6 SD.
Abbreviations: ACE 5 angiotensin-converting enzyme; DBP 5 diastolic blood
pressure; HR 5 heart rate; MI 5 myocardial infarction; SBP 5 systolic blood
pressure.
Table 2. Ischemic Events and Angiographic Parameters
Events
Nicorandil
(n 5 40)
Control
(n 5 41)
p
Value
Extension 2 (6) 1 (2) 0.61
Early PIA 1 (3) 1 (2) 0.98
Late PIA 1 (3) 3 (7) 0.32
Coronary restenosis 1 (3) 2 (5) 0.53
Coronary reocclusion 1 (3) 2 (5) 0.53
Data are presented number of patients (percent).
Abbreviations: Early PIA 5 postinfarction angina observed within 7 days after the
onset of the infarction; Late PIA 5 postinfarction angina observed after 7 days of the
infarction (mainly detected by late stage bicycle ergometer test).
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group. Congestive heart failure was observed more fre-
quently #3 days of the AMI in the control group than in
the nicorandil group. Congestive heart failure, if it occurred,
tended to last beyond 3 days of AMI in the control group,
whereas it rarely lasted beyond 3 days in most of the
nicorandil group. Relative risk for each in-hospital compli-
cation with nicorandil was equal to 0.31 or less. No patient
in the nicorandil group died in the hospital. In contrast, 4
patients (10%) among the control group died, three patients
of CHF and one patient of acute cardiac rupture.
Left ventricular function and morphology. Table 4 com-
pares temporal changes in left ventricular (LV) global and
regional function and LV end-diastolic volume index
(LVEDVI) between the nicorandil and control groups.
Wall motion score significantly decreased from baseline to
follow-up study in both groups. However, the magnitude of
reduction was significantly greater in the nicorandil group
than in the control group. An increase in regional wall
motion was significantly greater in the nicorandil group
than in the control group. Whereas LVEDVI decreased in
the nicorandil group, it increased in the control group. But
this difference did not reach statistical significance.
We also analyzed LV functional and morphological
outcomes in patients who underwent angioplasty less than
6 h after the symptom onset (Table 5). In this population,
the improvement in regional function, such as wall motion
score and regional wall motion, was also significantly better
in the nicorandil group than in the control group. Again
LVEDVI decreased in the nicorandil group and increased
in the control group, as was observed in the whole popula-
tion of patients. However, this difference in changes in left
ventricular volume reached statistical significance in this
early reperfusion group.
Hemodynamics and microvascular integrity. Both sys-
tolic blood pressure and pulmonary capillary wedge pressure
showed comparable value between the control and nicoran-
Table 3. In-Hospital Complications
Complications
Nicorandil
(n 5 40)
Control
(n 5 41)
Relative Risk
with Nicorandil
(95% CI)
p
Value
VT or Vf 2 (5) 8 (20) 0.22 (0.04 to 1.10) 0.048
Pericardial effusion 3 (8) 15 (37) 0.14 (0.04 to 0.54) 0.001
Cardiac tamponade 0 (0) 4 (10) — 0.043
Early CHF 6 (15) 15 (37) 0.31 (0.10 to 0.90) 0.027
Late CHF 1 (3) 5 (12) 0.18 (0.02 to 1.66) 0.028
In-hospital death 0 (0) 4 (10) — 0.043
Data are presented number of patients (percent). Presence or absence of VT or Vf were evaluated within 24 h after coronary
reperfusion.
Abbreviations: CHF 5 congestive heart failure; CI 5 confidence interval; Early 5 within 3 days after the infarction; Late 5
beyond third day after the infarction; VT 5 ventricular tachycardia; Vf 5 ventricular fibrillation.
Table 4. Functional Outcomes (Whole Patients)
Nicorandil
(n 5 40)
Control
(n 5 37)
p
Value
WMS
Acute 16 6 6 18 6 6 0.220
Late 10 6 6 15 6 7 0.001
Late 2 acute 26 6 5 23 6 4 0.001
LVEF (%)
Acute 42 6 8 44 6 9 0.359
Late 52 6 11 47 6 13 0.180
Late 2 acute 9 6 9 6 6 10 0.215
RWM (SD/chord)
Acute 22.4 6 0.6 22.6 6 0.9 0.342
Late 21.7 6 0.6 22.4 6 1.0 0.001
Late 2 Acute 0.7 6 0.5 0.2 6 0.7 0.001
LVEDVI (ml/mm2)
Acute 104 6 26 102 6 25 0.759
Late 102 6 27 105 6 29 0.704
Late 2 acute 22 6 15 4 6 25 0.298
Date are presented mean value 6 SD. The number of patients in the control group
is reduced by four compared to the baseline number, because of in-hospital death.
Abbreviations: Acute 5 day 1; Late 5 day 21 in measuring WMS, day 25 in
measuring LVEF, RWM and LVEDVI; LVEDVI 5 left ventricular end-diastolic
volume index; RWM 5 regional wall motion; WMS 5 wall motion score.
Table 5. Functional Outcomes (Cases of Onset–Reperfusion
Time #6 h)
Nicorandil
(n 5 31)
Control
(n 5 27)
p
Value
WMS
Acute 16 6 6 20 6 6 0.114
Late 9 6 5 16 6 8 0.001
Late 2 acute 27 6 4 23 6 4 0.001
LVEF (%)
Acute 42 6 7 41 6 9 0.941
Late 52 6 10 47 6 14 0.250
Late 2 acute 10 6 10 6 6 10 0.193
RWM (SD/chord)
Acute 22.6 6 0.5 22.7 6 0.9 0.645
Late 21.8 6 0.6 22.4 6 1.0 0.004
Late 2 acute 0.8 6 0.6 0.3 6 0.6 0.003
LVEDVI (ml/mm2)
Acute 103 6 23 97 6 21 0.368
Late 102 6 25 108 6 24 0.547
Late 2 acute 22 6 17 12 6 19 0.033
Data are presented mean value 6 SD. Abbreviations as in Table 4.
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dil groups at both baseline and follow-up studies (nicorandil
vs. control: pulmonary capillary wedge pressure, 9 6 5 vs.
10 6 6 mm Hg; cardiac index, 3.3 6 0.6 vs. 3.2 6 0.9
L/min/m2, systolic blood pressure, 112 6 19 vs. 122 6
16 mm Hg). However, the frequency of MCE no reflow in
the nicorandil group was lower by .50% than that in the
control group (15% vs. 33%, P , 0.05) (Fig. 1). Relative risk
for each MCE no reflow with nicorandil was 0.34. There-
fore, the differences in the improvement in regional left
ventricular function and frequencies of in-hospital compli-
cations between the control and nicorandil groups may be
explained by the difference in the severity of microvascular
damages.
DISCUSSION
Intravenous nicorandil and clinical outcomes. Improve-
ment in regional LV function was significantly better in the
nicorandil group than in the control group. Although CHF
was observed with similar frequency on admission between
two groups, it more frequently lasted beyond 3 days after
angioplasty in the control group than in the nicorandil
group. This better functional improvement in the nicorandil
group should be explained by the lower incidence of MCE
no reflow in this group. The no reflow phenomenon is
located within the area of myocardial necrosis (19–21);
thus, the greater size of no reflow as in cases of MCE no
reflow should imply the greater size of AMI; thus, it may
take longer for the left ventricle to adapt to it. An increase
in myocardial blood to the jeopardized myocardium with
nicorandil would lead to the reduction of the infarct size.
The difference in duration of CHF between the two groups
may be explained this way.
Frequency of either pericardial effusion or cardiac tam-
ponade was significantly lower in the nicorandil group than
in the control group. Frequency of malignant ventricular
arrhythmia was also significantly lower in the nicorandil
group than in the control group. In the previous study, we
also reported that the frequencies of pericardial effusion,
cardiac tamponade and reperfusion arrhythmia are signifi-
cantly higher in patients with MCE no reflow than in those
with MCE reflow. The broad and extensive myocardial
damage in cases of MCE no reflow may contribute to the
occurrence of malignant ventricular arrhythmia, pericarditis
or oozing rupture (18). Thus, the lower frequencies of
post-AMI complications in the nicorandil group should be
explained by the lower incidence of MCE no reflow of this
group.
Left ventricular remodeling is sometimes observed during
the early convalescent period of AMI. Although this dila-
tion appears to represent a compensatory mechanism for
suppressed LV function, it sometimes profoundly damages
LV function and affects patient prognoses. Although coro-
nary reperfusion per se might have a beneficial effect of
preventing LV dilation, a substantial population (19% to
42%) of patients still manifest significant LV dilation
(22–24). Among patients with reperfused AMI, we previ-
ously reported that MCE no flow can strongly discriminate
patients with LV dilation from those with MCE reflow.
This is because the sizable no reflow phenomenon indicates
the presence of greater size of AMI.
In this study, LVEDVI decreased from acute to late stage
of AMI in the nicorandil group, whereas it increased in the
control group. This finding was more evident in patients
who underwent angioplasty within 6 h after the symptom
onset. This result may be explained by the lower frequency
of MCE no reflow in the nicorandil group. In addition to
the possible smaller size of AMI in the nicorandil group,
success of coronary perfusion at microcirculation may en-
hance the healing process of infarct tissue. Reduction of LV
load with nicorandil may play an additional role in the
prevention of LV dilation, although the hemodynamic
variables were not different between the two groups.
Comparison with previous studies. In the previous study
(5), we injected verapamil into the infarct-related artery
after angioplasty in patients with AMI. We observed a
decrease in size of the no reflow phenomenon and an
increase in contrast peak intensity, which imply improve-
ment in the microvascular function. This was associated
with better improvement in LV function than angioplasty
alone. Recently, Sakata et al. reported that the single
administration of intracoronary nicorandil after angioplasty
improves microvascular function, which was associated with
better recovery of postischemic myocardial function in
patients with AMI (4). In these studies, verapamil or
nicorandil was injected directly into the coronary artery only
after the presence or absence of no reflow phenomenon was
judged with MCE. In contrast with these studies, we
continuously injected nicorandil intravenously in the present
study, but a similar salutary effect was demonstrated.
This may be explained by the difference in the onset and
duration of the drug administration. We initiated the
intravenous nicorandil just after the diagnosis of AMI was
Figure 1. Comparison of frequency of MCE no reflow between
nicorandil and control groups. Frequency of MCE no reflow was
significantly lower in the nicorandil group than in the control
group. Relative risk for MCE no reflow with nicorandil was 0.34.
Abbreviations: CI 5 confidence interval; MCE 5 myocardial
contrast echocardiography.
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established, and it was at least 30 min before angioplasty.
This was because we considered it hard to deliver nicorandil
into the whole risk area, once the no reflow phenomenon is
established. In an experimental study, Villanueva et al. (25)
documented that the size of no reflow is minimal at the
moment of coronary reperfusion, and it increases until
15 min after reperfusion, at which point we usually evaluate
the presence or absence of this phenomenon in the clinical
setting. This result indicates that myocardial blood flow may
once be present even in no reflow zone. In such an instance,
nicorandil may be effectively delivered to the postischemic
microvascular beds on the blood flow at reperfusion. Addi-
tionally, nicorandil may also be delivered to the risk area by
collateral flow before coronary reperfusion.
We continued the intravenous injection of nicorandil at
least 24 h followed by the oral administration. Several
studies have demonstrated that the no reflow phenomenon
may progress for several hours after coronary reperfusion
(26,27). The continuous infusion of nicorandil may restrain
the progression of microvascular damages.
Possible mechanisms. Several mechanisms were postu-
lated to explain the direct cardioprotective effect of nicoran-
dil. First, opening of the KATP channel in the ischemic
myocardium shortens the duration of the action potential
and inhibits voltage-dependent Ca21 channels and Na1/
Ca21 exchange. Because Ca21 overload in myocyte causes
cellular damage, the inhibition of these routes for Ca21
influx may largely contribute to cardioprotection. Second,
nicorandil reduces neutrophil infiltration into the ischemic
myocardium (8,10). It also attenuates the activity of neu-
trophil in a concentration-dependent manner (28). This
reduction may attenuate microvascular injury caused by
neutrophil, leading to an increase in myocardial blood flow.
The attachment and migration of neutrophil through in-
flamed vessels is dependent on shear rate, and an increase in
shear rate due to an increase in microvascular flow may also
reduce neutrophil recruitment. An increase in blood flow
can enhance the functional improvement of stunned myo-
cardium (29). Third, this may be related to the hemody-
namic effect that is characterized by a reduction of preload
and/or afterload. Finally, the vessels ,100 mm are more
sensitive to nicorandil than other size vessels (30).
The characteristic of nicorandil to reduce infarct size
when given after coronary occlusion is not shared by other
KATP channel openers. In fact, bimakalim exerts its protec-
tive effects so long as it is given before the onset of ischemia,
whereas it has no beneficial effect when administrated only
during the reperfusion period (31–33). The difference be-
tween nicorandil and bimakalim can be explained only by
supporting that a mechanism other than KATP channel
opening is responsible for the cardioprotective effect of
nicorandil. This may be in part explained by its nitrates
activity.
Limitations. We selected the maximal intravenous dose
allowed for the treatment of unstable angina pectoris and
the oral dose routinely used in patients with angina pectoris.
The optimal dose and protocol of nicorandil may be
different from the protocol of this study. Our analysis was
based on a comparison of in-hospital complications and
functional outcomes only; survival and quality of life in a
longer follow-up period were not taken into consideration.
The salutary effect of intravenous nicorandil has not been
established in patients with an inferior or posterior wall
AMI or a recurrent AMI.
Myocardial contrast echocardiography data should be
considered in light of several limitations. First, our method
depends on image quality. Second, contrast intensity is
influenced by many factors, including the size and number
of microbubbles, factors altering ultrasonic reflection such as
gain setting, depth of penetration, incident angle, axial and
lateral resolution, gray scale compression and the nonlinear-
ity of echo amplitude signals.
Clinical implications. Assessment of microvascular perfu-
sion with MCE seems to be essential in gaining further
understanding of patients’ outcome and of the relation
between intervention and outcome, since MCE is a useful
method available for assessment of microvascular integrity.
The prompt assessment of both coronary anatomy and the
quality of microvascular perfusion and hence myocardial
viability may aid in decision making in individual patients.
Our results indicated that the intravenous nicorandil par-
tially restrains ischemic microvascular damages and,
thereby, augments myocardial blood flow. This was associ-
ated with better functional and clinical outcomes than
angioplasty alone. Thus, we should achieve and maintain
not only the patency of the epicardial coronary artery but
also that of coronary microvasculature with pharmacologic
intervention to achieve an optimal myocardial salve in AMI.
Myocardial contrast echocardiograhy provides a useful
method to promptly evaluate the salutary effect of these
drugs on coronary microcirculation.
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